Victory in EPO opposition safeguards patent for breakthrough hyperkalaemia drug


Relypsa is a biopharmaceutical company focused on the development and commercialisation of late-stage medicines in the iron deficiency, nephrology and cardio-renal therapeutic areas. Priding itself on innovation, it had developed the first new treatment for hyperkalaemia (a complication of advanced chronic kidney failure and/or treatments for heart failure) for 50 years. 

The product - Veltassa® - received European marketing approval in 2017. In 2018, we preserved the European patent in a successful defence in EPO opposition proceedings filed by two generic pharmaceutical manufacturers. 


The successful outcome of the case means that Relypsa faces less of a threat of competition for Veltassa® as an oral treatment for hyperkalaemia. With the worldwide market for hyperkalaemia treatments forecast to reach annual sales of $2bn in the next few years, this was hugely significant result for the client.